Vasoactive medications in extremely low gestational age neonates during the first postnatal week
Objective The management of early hypotension in extremely low gestational age neonates (ELGANs) varies greatly between centers. The objective of this study was to provide updated data on the use of vasoactive medications in ELGANs during the first postnatal week. Study design We identified ELGANs (...
Gespeichert in:
Veröffentlicht in: | Journal of perinatology 2021-09, Vol.41 (9), p.2330-2336 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Objective
The management of early hypotension in extremely low gestational age neonates (ELGANs) varies greatly between centers. The objective of this study was to provide updated data on the use of vasoactive medications in ELGANs during the first postnatal week.
Study design
We identified ELGANs (22–27 weeks gestational age) cared for at Pediatrix neonatal intensive care units from 2009 to 2018. We evaluated the frequency of exposure to vasoactive medications by gestational age, and compared use of vasoactive medications between two epochs (2009–2013 and 2014–2018).
Results
A total of 10,070/34,234 (29%) ELGANs received ≥1 vasoactive medication. Dopamine was the most frequently used vasoactive medication. The majority (83%) of treated ELGANs initiated therapy on postnatal days 0–1. Overall use of vasoactive medications was slightly lower in 2014–2018 than 2009–2013 (28 vs 31%,
p
|
---|---|
ISSN: | 0743-8346 1476-5543 |
DOI: | 10.1038/s41372-021-01031-8 |